
Raymond J. Henley Iii
Examiner (ID: 7179, Phone: (571)272-0575 , Office: P/1629 )
| Most Active Art Unit | 1614 |
| Art Unit(s) | 1205, 2899, 1629, 1614, 1621 |
| Total Applications | 4324 |
| Issued Applications | 3034 |
| Pending Applications | 603 |
| Abandoned Applications | 710 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 12150048
[patent_doc_number] => 20180021313
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'Methazolamide for the treatment of cancer'
[patent_app_type] => utility
[patent_app_number] => 15/651060
[patent_app_country] => US
[patent_app_date] => 2017-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 7053
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15651060
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/651060 | Methazolamide for the treatment of cancer | Jul 16, 2017 | Issued |
Array
(
[id] => 12085931
[patent_doc_number] => 09839645
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-12-12
[patent_title] => 'Agents for killing HIV-1-infected cells and application thereof'
[patent_app_type] => utility
[patent_app_number] => 15/651667
[patent_app_country] => US
[patent_app_date] => 2017-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 7340
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15651667
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/651667 | Agents for killing HIV-1-infected cells and application thereof | Jul 16, 2017 | Issued |
Array
(
[id] => 12022165
[patent_doc_number] => 20170312265
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-11-02
[patent_title] => 'METHOD FOR IMPROVING INTERSTITIAL FLOW'
[patent_app_type] => utility
[patent_app_number] => 15/650554
[patent_app_country] => US
[patent_app_date] => 2017-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 14242
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650554
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/650554 | Method for improving interstitial flow | Jul 13, 2017 | Issued |
Array
(
[id] => 13035335
[patent_doc_number] => 10039780
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-07
[patent_title] => Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
[patent_app_type] => utility
[patent_app_number] => 15/643745
[patent_app_country] => US
[patent_app_date] => 2017-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22617
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15643745
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/643745 | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same | Jul 6, 2017 | Issued |
Array
(
[id] => 13136295
[patent_doc_number] => 10085452
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-10-02
[patent_title] => Synergistic benzoxaborole-containing anti-fungicidal composition
[patent_app_type] => utility
[patent_app_number] => 15/644063
[patent_app_country] => US
[patent_app_date] => 2017-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19653
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 135
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644063
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/644063 | Synergistic benzoxaborole-containing anti-fungicidal composition | Jul 6, 2017 | Issued |
Array
(
[id] => 12000341
[patent_doc_number] => 20170304496
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-10-26
[patent_title] => 'POLYURETHANES FOR OSTEOIMPLANTS'
[patent_app_type] => utility
[patent_app_number] => 15/643137
[patent_app_country] => US
[patent_app_date] => 2017-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10031
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15643137
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/643137 | Polyurethanes for osteoimplants | Jul 5, 2017 | Issued |
Array
(
[id] => 12117308
[patent_doc_number] => 20180000894
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-04
[patent_title] => 'MESALAMINE FOR THE TREATMENT OF CANCER'
[patent_app_type] => utility
[patent_app_number] => 15/637007
[patent_app_country] => US
[patent_app_date] => 2017-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 6943
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15637007
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/637007 | Mesalamine for the treatment of cancer | Jun 28, 2017 | Issued |
Array
(
[id] => 12043400
[patent_doc_number] => 09820984
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2017-11-21
[patent_title] => 'Dosing regimens for fast onset of antidepressant effect'
[patent_app_type] => utility
[patent_app_number] => 15/636238
[patent_app_country] => US
[patent_app_date] => 2017-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 15353
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15636238
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/636238 | Dosing regimens for fast onset of antidepressant effect | Jun 27, 2017 | Issued |
Array
(
[id] => 12151450
[patent_doc_number] => 20180022713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-01-25
[patent_title] => 'HETEROARYL COMPOUNDS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 15/635954
[patent_app_country] => US
[patent_app_date] => 2017-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 65142
[patent_no_of_claims] => 65
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15635954
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/635954 | Heteroaryl compounds and uses thereof | Jun 27, 2017 | Issued |
Array
(
[id] => 12701920
[patent_doc_number] => 20180125806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-10
[patent_title] => NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES
[patent_app_type] => utility
[patent_app_number] => 15/629277
[patent_app_country] => US
[patent_app_date] => 2017-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629277
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/629277 | Nitrated-fatty acids modulation of type II diabetes | Jun 20, 2017 | Issued |
Array
(
[id] => 12701920
[patent_doc_number] => 20180125806
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-10
[patent_title] => NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES
[patent_app_type] => utility
[patent_app_number] => 15/629277
[patent_app_country] => US
[patent_app_date] => 2017-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15629277
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/629277 | Nitrated-fatty acids modulation of type II diabetes | Jun 20, 2017 | Issued |
Array
(
[id] => 14306149
[patent_doc_number] => 20190142778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-16
[patent_title] => TREATMENT FOR MYOPIA
[patent_app_type] => utility
[patent_app_number] => 16/310587
[patent_app_country] => US
[patent_app_date] => 2017-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14441
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310587
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/310587 | Treatment for myopia | Jun 20, 2017 | Issued |
Array
(
[id] => 15035477
[patent_doc_number] => 20190328743
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-31
[patent_title] => EZH2 INHIBITORS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/310597
[patent_app_country] => US
[patent_app_date] => 2017-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310597
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/310597 | EZH2 inhibitors for treating cancer | Jun 15, 2017 | Issued |
Array
(
[id] => 16381911
[patent_doc_number] => 10806721
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-20
[patent_title] => Formulation for use in the treatment of uremic pruritus
[patent_app_type] => utility
[patent_app_number] => 16/310025
[patent_app_country] => US
[patent_app_date] => 2017-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 5649
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310025
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/310025 | Formulation for use in the treatment of uremic pruritus | Jun 15, 2017 | Issued |
Array
(
[id] => 14116873
[patent_doc_number] => 10245277
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-02
[patent_title] => Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
[patent_app_type] => utility
[patent_app_number] => 15/624275
[patent_app_country] => US
[patent_app_date] => 2017-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 23504
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624275
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/624275 | Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection | Jun 14, 2017 | Issued |
Array
(
[id] => 15020693
[patent_doc_number] => 20190321351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-24
[patent_title] => METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND EXPOSURE TO NERVE AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/309898
[patent_app_country] => US
[patent_app_date] => 2017-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309898
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/309898 | Methods for treating neurological conditions and exposure to nerve agents | Jun 8, 2017 | Issued |
Array
(
[id] => 11969791
[patent_doc_number] => 20170273945
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2017-09-28
[patent_title] => 'PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION'
[patent_app_type] => utility
[patent_app_number] => 15/618313
[patent_app_country] => US
[patent_app_date] => 2017-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 11120
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618313
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/618313 | Pharmaceutical composition for topical administration | Jun 8, 2017 | Issued |
Array
(
[id] => 14578345
[patent_doc_number] => 20190216781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => METHODS FOR TREATING HETEROTOPIC OSSIFICATION
[patent_app_type] => utility
[patent_app_number] => 16/308012
[patent_app_country] => US
[patent_app_date] => 2017-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308012
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/308012 | Methods for treating heterotopic ossification | Jun 7, 2017 | Issued |
Array
(
[id] => 13065269
[patent_doc_number] => 10053407
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-21
[patent_title] => Crystalline cannabidivarin
[patent_app_type] => utility
[patent_app_number] => 15/609159
[patent_app_country] => US
[patent_app_date] => 2017-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 9474
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 3
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15609159
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/609159 | Crystalline cannabidivarin | May 30, 2017 | Issued |
Array
(
[id] => 12367257
[patent_doc_number] => 09957287
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-05-01
[patent_title] => Methods and compositions to treat type-1 and type-2 diabetes
[patent_app_type] => utility
[patent_app_number] => 15/604201
[patent_app_country] => US
[patent_app_date] => 2017-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 12045
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15604201
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/604201 | Methods and compositions to treat type-1 and type-2 diabetes | May 23, 2017 | Issued |